InvestorsHub Logo
Followers 74
Posts 3281
Boards Moderated 0
Alias Born 03/16/2014

Re: notbrad post# 130896

Tuesday, 08/22/2017 9:42:26 AM

Tuesday, August 22, 2017 9:42:26 AM

Post# of 705628
Mouthwatering prospect...

There is no doubt Gilead need to hedge their Hep C future flows as they will significantly taper beyond 2022. Remember they paid $11bn for Pharmasset and that ended up being a great trade for them.

Also JNJ have $41bn in cash ....

In fact all large pharma could finance $10bn in a heart beat ..
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News